384
Participants
Start Date
November 10, 2020
Primary Completion Date
May 31, 2021
Study Completion Date
July 28, 2021
Convalescent anti-SARS-CoV-2 MBT plasma
Subjects randomized to combination convalescent anti-SARS-CoV-2 MBT plasma plus SMT will undergo an ABO compatibility test and will receive a single infusion of 200 to 300 ml of ABO-compatible convalescent plasma
Control Group
Subjects randomized to placebo plus SMT will receive one infusion of 200 to 300ml of sterile saline solution 0.9%.
Germans Trias i Pujol Hospital, Badalona
Hospital Sant Bernabé (Hospital de Berga), Berga
CUAP Manresa (Planta 0 del CAP Bages), Manresa
Hospital Universitari de Bellvitge, Barcelona
Germans Trias i Pujol Hospital
OTHER
IrsiCaixa
OTHER
Banc de Sang i Teixits
OTHER
Grifols Biologicals, LLC
INDUSTRY
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
OTHER